Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Video

Updated: Nov 7, 2025

Predictive Immune Modeling of Solid Tumors

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

A prognostic immune risk score for diffuse large B-cell lymphoma.

Shu-Yun Ma^1,2, Xiao-Peng Tian^1,2, Jun Cai^1,2

¹Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, P. R. China.

British Journal of Haematology

|May 4, 2021

Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Liposomal mitoxantrone plus tislelizumab in patients with relapsed or refractory extranodal natural killer/T-cell lymphoma: a phase 1b/2 trial.

Nature communications·2026

Same author

TQB2618 plus penpulimab, alone or in combination with chemotherapy, for recurrent or metastatic nasopharyngeal carcinoma: a multicentre, two-cohort, phase 2 trial.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Same author

Treatment Patterns and Clinical Outcomes After Immunotherapy Failure in Patients With Natural Killer/T-Cell Lymphoma.

American journal of hematology·2026

Same author

Treatment evolution and survival impact of consolidation therapies in mantle cell lymphoma: insights from an Asia-Pacific real-world registry.

Blood cancer journal·2026

Same author

Jargon redux.

Bone marrow transplantation·2026

Same author

Site-specific methylation of SRSF2<sup>P95H</sup> by SETD2 inhibits MDSC-mediated proinflammatory niche formation in mouse models of myelodysplastic syndrome.

Science translational medicine·2026

A new immune risk score accurately predicts survival in diffuse large B-cell lymphoma (DLBCL) patients. This score, based on infiltrating immune cells, outperforms existing prognostic indices like IPI and R-IPI for DLBCL prognosis.

Area of Science:

Oncology
Immunology
Bioinformatics

Background:

Diffuse large B-cell lymphoma (DLBCL) is an aggressive non-Hodgkin lymphoma.
Accurate prognostic markers are crucial for guiding treatment decisions in DLBCL.
Existing prognostic indices may not fully capture the tumor microenvironment's role.

Purpose of the Study:

To develop and validate a novel prognostic score for DLBCL patients based on tumor-infiltrating immune cells.
To assess the predictive accuracy of this immune risk score compared to established indices.

Main Methods:

Utilized Gene Expression Omnibus (GEO) data from 956 DLBCL patients (training and validation cohorts).
Employed ESTIMATE and CIBERSORT algorithms to infer immune cell proportions and construct an immune risk score.

Keywords:

diffuse large B-cell lymphoma gene expression immune risk score micro-environment prognosis

More Related Videos

Author Spotlight: Multiplex Immunofluorescence Combined with Spatial Image Analysis for the Clinical and Biological Assessment of the Tumor Microenvironment

Author Spotlight: Multiplex Immunofluorescence Combined with Spatial Image Analysis for the Clinical and Biological Assessment of the Tumor Microenvironment

Published on: June 2, 2023

Enhancing Tumor Content through Tumor Macrodissection

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

Related Experiment Videos

Last Updated: Nov 7, 2025

Predictive Immune Modeling of Solid Tumors

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

Author Spotlight: Multiplex Immunofluorescence Combined with Spatial Image Analysis for the Clinical and Biological Assessment of the Tumor Microenvironment

Author Spotlight: Multiplex Immunofluorescence Combined with Spatial Image Analysis for the Clinical and Biological Assessment of the Tumor Microenvironment

Published on: June 2, 2023

Enhancing Tumor Content through Tumor Macrodissection

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

Compared the immune risk score's performance against the International Prognostic Index (IPI) and Revised International Prognostic Index (R-IPI).

Main Results:

The constructed immune risk score significantly predicted five-year survival in both training and validation cohorts (HR=3.99, P<0.001; HR=2.17, P<0.001).
A nomogram incorporating the immune risk score achieved a higher C-statistic (0.76) than IPI (0.69) and R-IPI (0.69).
Enrichment analyses revealed correlations between the immune risk score and immune-related biological processes.

Conclusions:

The developed immune risk score is an accurate and independent predictor of survival in DLBCL patients.
This immune-based score offers improved prognostic capability over current clinical indices.
The findings highlight the importance of the immune microenvironment in DLBCL pathogenesis and prognosis.